The medical device and equipment maker backed by SR One and Novo raises a further $7.5m.
HTG Molecular Diagnostics, a medical device and equipment maker, has raised $7.5m of a planned $27m round, according to a November 14 filing with US regulator Securities and Exchange Commission.
HTG previously raised $15.7m in a Series D round led by Novo.
SR One joined the second tranche of HTG’s series D round financing. The tranche also included Merck Capital Ventures, the corporate venturing unit of the eponymous drugs company, early stage investor Solstice Capital and US venture…
